$DRREDDY Stock In Focus: Dr. Reddy's Laboratories (DRREDDY)

$DRREDDY Monday was a bruising session. Sensex closed down 372 points at 76,728 and Nifty slipped 109 points to 23,946, weighed down by renewed US-Iran tensions over the weekend, with IT, auto and banking stocks leading the fall. But one name bucked the tide — Dr. Reddy's Laboratories was among Monday's top Nifty gainers, rising 4.4% even as broader markets bled. Simply Wall That outperformance deserves a closer look heading into Tuesday. The longer story: the stock's 52-week range runs from Rs 1,143.05 to Rs 1,377.95, with the current level sitting roughly 7-8% below the 52-week high — suggesting meaningful room before it revisits prior peaks. Q4 FY26 net profit collapsed 86.14% year on year to Rs 220.90 crore, with operating margins plunging to just 5.09% from 23.49% a year ago — a sharp one-quarter shock driven largely by the lenalidomide patent expiry impact. However, the company carries zero net debt, has delivered a 5-year sales CAGR of 13.12%, and maintains an average ROCE of 20.50% — fundamentals that remain intact beneath the surface noise. Nomura has upgraded its target with a Buy rating, citing Dr. Reddy's strategic shift toward branded generics and expecting the consumer business to sustain earnings growth and drive valuation re-rating. Q1 FY27 results are scheduled for July 22 — making the coming weeks a critical window to watch for early signs of margin recovery. Pharma was among the few sectors that showed relative resilience on Monday even as the broader market fell. If that sectoral bid continues into Tuesday, Dr. Reddy's could be one of the key counters to watch.